The Filings Report

Medtronic plc

MDTNYSECIK 1613103Healthcare / Medical Devicesfiscal year ends April53 quarters since 2013

Revenue, Q1 FY2027
$9.8B
+13.7% on Q1 FY2026
Net income
$1.5B
+41.3% on Q1 FY2026
Free cash flow
$1.3B
+120.9% on Q1 FY2026
Diluted EPS
$1.14
+40.7% on Q1 FY2026
Revenue, TTM
$37.5B
trailing four quarters
Net margin, TTM
13.9%
net income $5.2B
Free cash flow, TTM
$6.1B
$8.0B less $1.9B capex
Cash and equivalents
$1.7B
long-term debt —, Jul 31, 2026
Shares, 12-month change
−0.3%
1.28B shares, Jul 31, 2026
Buybacks, TTM
$1.2B
0.9% of market value
Dividends, TTM
$3.6B
3.0% of market value
Market value
$123.5B
at the close, buybacks

Latest quarter Q1 FY2027, filed September 3, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q1 FY2027, the quarter ended July 31, 2026, Medtronic plc reported revenue of $9.8B, +13.7% on Q1 FY2026, and net income of $1.5B (+41.3%). Operating margin was 18.1%. Free cash flow, operating cash flow less capital expenditures, was $1.3B ($1.8B less $503M). Diluted earnings per share were $1.14.

The last 16 quarters

Q2 FY2023 to Q1 FY2027, through the filing of September 3, 2026.

Revenue and net incomeRevenueNet income
$0$3B$5B$8B$10BQ2'23, Revenue: $7.6BQ2'23, Net income: $427MQ2'23Q3'23, Revenue: $7.7BQ3'23, Net income: $1.2BQ3'23Q4'23, Revenue: $8.5BQ4'23, Net income: $1.2BQ4'23Q1'24, Revenue: $7.7BQ1'24, Net income: $791MQ1'24Q2'24, Revenue: $8.0BQ2'24, Net income: $909MQ2'24Q3'24, Revenue: $8.1BQ3'24, Net income: $1.3BQ3'24Q4'24, Revenue: $8.6BQ4'24, Net income: $654MQ4'24Q1'25, Revenue: $7.9BQ1'25, Net income: $1.0BQ1'25Q2'25, Revenue: $8.4BQ2'25, Net income: $1.3BQ2'25Q3'25, Revenue: $8.3BQ3'25, Net income: $1.3BQ3'25Q4'25, Revenue: $8.9BQ4'25, Net income: $1.1BQ4'25Q1'26, Revenue: $8.6BQ1'26, Net income: $1.0BQ1'26Q2'26, Revenue: $9.0BQ2'26, Net income: $1.4BQ2'26Q3'26, Revenue: $9.0BQ3'26, Net income: $1.1BQ3'26Q4'26, Revenue: $9.8BQ4'26, Net income: $1.2BQ4'26Q1'27, Revenue: $9.8BQ1'27, Net income: $1.5BQ1'27$0$3B$5B$8B$10BQ2'23, Revenue: $7.6BQ2'23, Net income: $427MQ3'23, Revenue: $7.7BQ3'23, Net income: $1.2BQ3'23Q4'23, Revenue: $8.5BQ4'23, Net income: $1.2BQ1'24, Revenue: $7.7BQ1'24, Net income: $791MQ1'24Q2'24, Revenue: $8.0BQ2'24, Net income: $909MQ3'24, Revenue: $8.1BQ3'24, Net income: $1.3BQ3'24Q4'24, Revenue: $8.6BQ4'24, Net income: $654MQ1'25, Revenue: $7.9BQ1'25, Net income: $1.0BQ1'25Q2'25, Revenue: $8.4BQ2'25, Net income: $1.3BQ3'25, Revenue: $8.3BQ3'25, Net income: $1.3BQ3'25Q4'25, Revenue: $8.9BQ4'25, Net income: $1.1BQ1'26, Revenue: $8.6BQ1'26, Net income: $1.0BQ1'26Q2'26, Revenue: $9.0BQ2'26, Net income: $1.4BQ3'26, Revenue: $9.0BQ3'26, Net income: $1.1BQ3'26Q4'26, Revenue: $9.8BQ4'26, Net income: $1.2BQ1'27, Revenue: $9.8BQ1'27, Net income: $1.5BQ1'27

Net income losses drawn in red.

Free cash flow
$0$1B$2B$3BQ2'23, Free cash flow: $599MQ2'23Q3'23, Free cash flow: $1.2BQ3'23Q4'23, Free cash flow: $2.1BQ4'23Q1'24, Free cash flow: $521MQ1'24Q2'24, Free cash flow: $200MQ2'24Q3'24, Free cash flow: $2.1BQ3'24Q4'24, Free cash flow: $2.4BQ4'24Q1'25, Free cash flow: $466MQ1'25Q2'25, Free cash flow: $554MQ2'25Q3'25, Free cash flow: $2.1BQ3'25Q4'25, Free cash flow: $2.1BQ4'25Q1'26, Free cash flow: $584MQ1'26Q2'26, Free cash flow: $457MQ2'26Q3'26, Free cash flow: $2.3BQ3'26Q4'26, Free cash flow: $2.1BQ4'26Q1'27, Free cash flow: $1.3BQ1'27$0$1B$2B$3BQ2'23, Free cash flow: $599MQ3'23, Free cash flow: $1.2BQ3'23Q4'23, Free cash flow: $2.1BQ1'24, Free cash flow: $521MQ1'24Q2'24, Free cash flow: $200MQ3'24, Free cash flow: $2.1BQ3'24Q4'24, Free cash flow: $2.4BQ1'25, Free cash flow: $466MQ1'25Q2'25, Free cash flow: $554MQ3'25, Free cash flow: $2.1BQ3'25Q4'25, Free cash flow: $2.1BQ1'26, Free cash flow: $584MQ1'26Q2'26, Free cash flow: $457MQ3'26, Free cash flow: $2.3BQ3'26Q4'26, Free cash flow: $2.1BQ1'27, Free cash flow: $1.3BQ1'27

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$2B$4B$6BQ2'23, Cash and equivalents: $4.8BQ2'23Q3'23, Cash and equivalents: $4.5BQ3'23Q4'23, Cash and equivalents: $1.5BQ4'23Q1'24, Cash and equivalents: $1.3BQ1'24Q2'24, Cash and equivalents: $1.3BQ2'24Q3'24, Cash and equivalents: $1.6BQ3'24Q4'24, Cash and equivalents: $1.3BQ4'24Q1'25, Cash and equivalents: $1.3BQ1'25Q2'25, Cash and equivalents: $1.4BQ2'25Q3'25, Cash and equivalents: $1.2BQ3'25Q4'25, Cash and equivalents: $2.2BQ4'25Q1'26, Cash and equivalents: $1.3BQ1'26Q2'26, Cash and equivalents: $1.3BQ2'26Q3'26, Cash and equivalents: $1.1BQ3'26Q4'26, Cash and equivalents: $1.9BQ4'26Q1'27, Cash and equivalents: $1.7BQ1'27$0$2B$4B$6BQ2'23, Cash and equivalents: $4.8BQ3'23, Cash and equivalents: $4.5BQ3'23Q4'23, Cash and equivalents: $1.5BQ1'24, Cash and equivalents: $1.3BQ1'24Q2'24, Cash and equivalents: $1.3BQ3'24, Cash and equivalents: $1.6BQ3'24Q4'24, Cash and equivalents: $1.3BQ1'25, Cash and equivalents: $1.3BQ1'25Q2'25, Cash and equivalents: $1.4BQ3'25, Cash and equivalents: $1.2BQ3'25Q4'25, Cash and equivalents: $2.2BQ1'26, Cash and equivalents: $1.3BQ1'26Q2'26, Cash and equivalents: $1.3BQ3'26, Cash and equivalents: $1.1BQ3'26Q4'26, Cash and equivalents: $1.9BQ1'27, Cash and equivalents: $1.7BQ1'27

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q1 FY2027 filed September 3, 2026.

Medtronic plc income statement, quarterly
Millions of dollarsQ1 FY2027ended Jul 31, 2026filed Sep 3, 2026Q4 FY2026ended Apr 24, 2026filed Jun 18, 2026Q3 FY2026ended Jan 23, 2026filed Feb 24, 2026Q2 FY2026ended Oct 24, 2025filed Nov 25, 2025Q1 FY2026ended Jul 25, 2025filed Aug 26, 2025Q4 FY2025ended Apr 25, 2025filed Jun 20, 2025Q3 FY2025ended Jan 24, 2025filed Feb 25, 2025Q2 FY2025ended Oct 25, 2024filed Nov 26, 2024YoYQ1 FY2027vs Q1 FY2026
Revenue9,7569,8079,0178,9618,5788,9278,2928,403+13.7%
Cost of revenue3,4163,3983,2613,0613,0013,1472,7792,946+13.8%
Gross profit—————————
Research and development771671722754726684675697+6.2%
Selling, general and administrative3,1983,0572,9562,9652,8062,7202,7172,757+14.0%
Operating income1,7641,8731,4641,6861,4451,4361,6461,595+22.1%
Other income (expense)1901371219233(1)72173+475.8%
Pretax income1,7691,8341,4041,5971,3021,2611,5401,559+35.9%
Income tax289575254215255199237281+13.3%
Net income1,4701,2441,1431,3741,0401,0561,2941,270+41.3%
Diluted EPS ($)1.14—0.891.070.81—1.010.99+40.7%
Diluted shares (millions)1,285—1,2901,2881,287—1,2861,287—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q1 FY2027 filed September 3, 2026.

Medtronic plc balance sheet, quarterly
Millions of dollarsQ1 FY2027ended Jul 31, 2026filed Sep 3, 2026Q4 FY2026ended Apr 24, 2026filed Jun 18, 2026Q3 FY2026ended Jan 23, 2026filed Feb 24, 2026Q2 FY2026ended Oct 24, 2025filed Nov 25, 2025Q1 FY2026ended Jul 25, 2025filed Aug 26, 2025Q4 FY2025ended Apr 25, 2025filed Jun 20, 2025Q3 FY2025ended Jan 24, 2025filed Feb 25, 2025Q2 FY2025ended Oct 25, 2024filed Nov 26, 2024YoYQ1 FY2027vs Q1 FY2026
Cash and equivalents1,6911,9491,1471,2821,2732,2181,2401,394+32.8%
Short-term investments7,1287,2717,2367,0456,8486,7476,6826,595+4.1%
Total current assets24,39024,78724,07123,99623,22323,81422,51322,438+5.0%
Total assets93,30693,02891,48591,34690,97291,68089,97390,042+2.6%
Total current liabilities11,79911,6589,4959,93511,53012,87911,84012,195+2.3%
Long-term debt—————————
Total liabilities42,45642,95642,28942,48942,83943,42440,35841,326−0.9%
Stockholders’ equity50,23249,46348,98548,65247,89348,02449,38748,494+4.9%
Shares outstanding (millions)1,2791,2801,2841,2821,2831,2811,2831,282—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q1 FY2027 filed September 3, 2026.

Medtronic plc cash flow statement, quarterly
Millions of dollarsQ1 FY2027ended Jul 31, 2026filed Sep 3, 2026Q4 FY2026ended Apr 24, 2026filed Jun 18, 2026Q3 FY2026ended Jan 23, 2026filed Feb 24, 2026Q2 FY2026ended Oct 24, 2025filed Nov 25, 2025Q1 FY2026ended Jul 25, 2025filed Aug 26, 2025Q4 FY2025ended Apr 25, 2025filed Jun 20, 2025Q3 FY2025ended Jan 24, 2025filed Feb 25, 2025Q2 FY2025ended Oct 25, 2024filed Nov 26, 2024YoYQ1 FY2027vs Q1 FY2026
Operating cash flow1,7932,5732,7449251,0882,5282,572958+64.8%
Capital expenditures503488444468504459476404−0.2%
Free cash flow (CFO − capex)1,2902,0852,3004575842,0692,096554+120.9%
Depreciation and amortization729716749745748840684675−2.5%
Share repurchases267435105372123274181288+117.1%
Dividends paid921908911910910897897897+1.2%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2026 filed June 18, 2026.

Income statement

Medtronic plc income statement, annual
Millions of dollarsFY2026ended Apr 24, 2026filed Jun 18, 2026FY2025ended Apr 25, 2025filed Jun 20, 2025FY2024ended Apr 26, 2024filed Jun 20, 2024FY2023ended Apr 28, 2023filed Jun 22, 2023FY2022ended Apr 29, 2022filed Jun 23, 2022FY2021ended Apr 30, 2021filed Jun 25, 2021FY2020ended Apr 24, 2020filed Jun 19, 2020FY2019ended Apr 26, 2019filed Jun 21, 2019FY2018ended Apr 27, 2018filed Jun 22, 2018FY2017ended Apr 28, 2017filed Jun 27, 2017FY2016ended Apr 29, 2016filed Jun 28, 2016FY2015ended Apr 24, 2015filed Jun 23, 2015FY2014ended Apr 25, 2014filed Jun 23, 2015FY2013ended Apr 26, 2013filed Jun 23, 2015
Revenue36,36433,53732,36431,22731,68630,11728,91330,55729,95329,71028,83320,26117,00516,590
Cost of revenue12,72111,63211,21610,71910,14510,4839,4249,1559,0679,2949,1426,3094,3334,126
Gross profit————————20,89820,41919,69113,95212,672—
Research and development2,8732,7322,7352,6962,7462,4932,3312,3302,2562,1932,2241,6401,4771,557
Selling, general and administrative11,78410,84910,73610,41510,29210,14810,10910,41810,23810,0189,4696,9045,8475,698
Operating income6,4675,9555,1445,4855,7524,4844,7916,2686,6405,3835,3613,7663,8134,402
Other income (expense)384402412515318336356373181313(107)(118)(181)(108)
Pretax income6,1365,6284,8375,3645,5173,8954,0555,1975,6754,6024,3363,4863,7054,251
Income tax1,2999361,1331,580456265(751)5472,580578798811640784
Net income4,8014,6623,6763,7585,0393,6064,7894,6313,1044,0283,5382,6753,0653,467
Diluted EPS ($)3.733.612.762.823.732.663.543.412.272.892.482.413.023.37
Diluted shares (millions)1,2881,2901,3301,3331,3511,3541,3511,3581,3681,3911,4261,1091,0141,028

Balance sheet

Medtronic plc balance sheet, annual
Millions of dollarsFY2026ended Apr 24, 2026filed Jun 18, 2026FY2025ended Apr 25, 2025filed Jun 20, 2025FY2024ended Apr 26, 2024filed Jun 20, 2024FY2023ended Apr 28, 2023filed Jun 22, 2023FY2022ended Apr 29, 2022filed Jun 23, 2022FY2021ended Apr 30, 2021filed Jun 25, 2021FY2020ended Apr 24, 2020filed Jun 19, 2020FY2019ended Apr 26, 2019filed Jun 21, 2019FY2018ended Apr 27, 2018filed Jun 22, 2018FY2017ended Apr 28, 2017filed Jun 27, 2017FY2016ended Apr 29, 2016filed Jun 28, 2016FY2015ended Apr 24, 2015filed Jun 23, 2015FY2014ended Apr 25, 2014filed Jun 23, 2015FY2013ended Apr 26, 2013filed Jun 23, 2015
Cash and equivalents1,9492,2181,2841,5433,7143,5934,1404,3933,6694,9672,8764,8431,403919
Short-term investments7,2716,7476,7216,4166,8597,2246,8085,4557,5588,7419,75814,63712,838—
Total current assets24,78723,81421,93521,67523,05922,54822,03121,96722,98024,87323,60030,84421,210—
Total assets93,02891,68089,98190,94890,98193,08390,68989,69491,39399,85799,644106,68537,943—
Total current liabilities11,65812,87910,7899,05112,3948,50910,3668,47210,08414,2647,1659,1735,559—
Long-term debt——————22,14024,55223,69225,87429,94433,171——
Total liabilities42,95643,42439,56139,28338,26041,48139,81739,48240,57149,52747,58153,45518,500—
Stockholders’ equity49,46348,02450,21451,48352,55151,42850,73750,09150,72050,20852,06353,23019,44318,671
Shares outstanding (millions)1,2801,2811,2821,3301,3291,3441,3411,3411,3521,3591,3951,416——

Cash flow statement

Medtronic plc cash flow statement, annual
Millions of dollarsFY2026ended Apr 24, 2026filed Jun 18, 2026FY2025ended Apr 25, 2025filed Jun 20, 2025FY2024ended Apr 26, 2024filed Jun 20, 2024FY2023ended Apr 28, 2023filed Jun 22, 2023FY2022ended Apr 29, 2022filed Jun 23, 2022FY2021ended Apr 30, 2021filed Jun 25, 2021FY2020ended Apr 24, 2020filed Jun 19, 2020FY2019ended Apr 26, 2019filed Jun 21, 2019FY2018ended Apr 27, 2018filed Jun 22, 2018FY2017ended Apr 28, 2017filed Jun 27, 2017FY2016ended Apr 29, 2016filed Jun 28, 2016FY2015ended Apr 24, 2015filed Jun 23, 2015FY2014ended Apr 25, 2014filed Jun 23, 2015FY2013ended Apr 26, 2013filed Jun 23, 2015
Operating cash flow7,3307,0446,7876,0397,3466,2407,2347,0074,6846,8805,2184,9024,959—
Capital expenditures1,9041,8591,5871,4591,3681,3551,2131,1341,0681,2541,046571396457
Free cash flow (CFO − capex)5,4265,1855,2004,5805,9784,8856,0215,8733,6165,6264,1724,3314,563—
Depreciation and amortization2,9582,8612,6472,6972,7072,7022,6632,6592,6442,9172,8201,306850819
Share repurchases1,0353,2352,1386452,5446521,3262,8772,1713,5442,8301,9202,5531,247
Dividends paid3,6393,5893,6663,6163,3833,1202,8942,6932,4942,3762,1391,3371,1161,055

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$6M
3 sales by 3 insiders; officers and directors $6M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$15M
18 sales by 5 insiders; officers and directors $15M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 15, 2026Lofton Kevin EDirectorother182——9,977Oct 21, 2026
Oct 15, 2026Marinaro MichaelEVP, Pres MedSurg and Americasopen-market sale10b5-110,420$96.00$1M105,916Oct 16, 2026
Oct 15, 2026Martha GeoffreyChairman and CEO, Directoropen-market sale10b5-150,000$95.00$5M277,866Oct 16, 2026
Oct 15, 2026Medtronic plc10% ownerother253M——0Oct 16, 2026
Sep 16, 2026Kiil Harry SkipEVP & President Cardiovascularopen-market sale1,483$93.65$139K42,186Sep 17, 2026
Sep 15, 2026Blomquist Denise L.Chief Accounting Officergift600$0.00—16,398Sep 16, 2026
Aug 20, 2026Marinaro MichaelEVP, Pres MedSurg and Americastax withholding1,084$92.30$100K116,336Aug 24, 2026
Aug 3, 2026Blomquist Denise L.Chief Accounting Officeraward2,337$0.00—16,998Aug 4, 2026
Aug 3, 2026Walter Matthew R.SVP, Chief HR Officeraward5,769$0.00—39,928Aug 4, 2026
Aug 3, 2026Thompson KweliEVP & President, Neuroscienceaward6,923$0.00—35,390Aug 4, 2026
Aug 3, 2026Quinn MichelleEVP, GC and Secretaryaward6,346$0.00—26,721Aug 4, 2026
Aug 3, 2026Pieton ThierryEVP & Chief Financial Officeraward11,537$0.00—49,645Aug 4, 2026
Aug 3, 2026Marinaro MichaelEVP, Pres MedSurg and Americasaward10,960$0.00—71,273Aug 4, 2026
Aug 3, 2026Marinaro MichaelEVP, Pres MedSurg and Americasaward46,147$0.00—117,420Aug 4, 2026
Aug 3, 2026Kiil Harry SkipEVP & President Cardiovascularaward9,230$0.00—43,669Aug 4, 2026
Aug 3, 2026Martha GeoffreyChairman and CEO, Directoraward41,533$0.00—327,866Aug 4, 2026
Jul 31, 2026Blomquist Denise L.Chief Accounting Officertax withholding212$85.39$18K14,661Aug 4, 2026
Jul 31, 2026Walter Matthew R.SVP, Chief HR Officertax withholding1,675$85.39$143K34,159Aug 4, 2026
Jul 31, 2026Thompson KweliEVP & President, Neurosciencetax withholding1,739$85.39$148K28,467Aug 4, 2026
Jul 31, 2026Marinaro MichaelEVP, Pres MedSurg and Americastax withholding3,356$85.39$287K60,313Aug 4, 2026
Jul 31, 2026Kiil Harry SkipEVP & President Cardiovasculartax withholding3,074$85.39$262K34,439Aug 4, 2026
Jul 31, 2026Martha GeoffreyChairman and CEO, Directortax withholding15,810$85.39$1M286,333Aug 4, 2026
Jul 28, 2026Quinn MichelleEVP, GC and Secretarytax withholding2,069$86.88$180K20,375Jul 29, 2026
Jul 8, 2026Walter Matthew R.SVP, Chief HR Officeropen-market sale10b5-13,102$83.15$258K35,694Jul 9, 2026
Jun 8, 2026Kiil Harry SkipEVP & President Cardiovascularopen-market sale3,961$80.44$319K37,455Jun 9, 2026

Full insider history for Medtronic plc, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 4; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Medtronic plc, CIK 1613103 on EDGAR
Extract generated
September 4, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated September 4, 2026.

JSON file
/data/financials/MDT.json